Frontera Therapeutics
- Biotech or pharma, therapeutic R&D
Frontera Therapeutics is a global clinical-stage biotechnology company committed to developing innovative and affordable rAAV gene therapies. Backed by world-renowned scientists/KOLs and funded by leading investors including ObiMed and Sequoia, we have developed an innovative pipeline covering both large and rare diseases in ophthalmology, hematology and cardiology.
Core asset, FT-003 (Phase 2), is a potential Best-in-Class anti-VEGF therapy for nAMD and DME, delivered via single intravitreal injection. Early clinical data demonstrate superior efficacy and safety versus major competitors.
Our Boston R&D Center has established a proprietary AAV capsids/ payloads engineering platform to develop vectors with strong tissue tropism, durable expression, and reduced immunogenicity
Our Suzhou GMP facility based on Sf9 system has reduced AAV COGS by 90% versus marketed products and minimized empty capsid rate <1% - ensuring high-quality and low-cost production for broad patient access.
)
)
){kind=logo}
){kind=logo}
){kind=logo}